

| | | | | | | | |
|--|--|--|--|------------------------------------|--|--------------------------|--|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | DOCKET NO. 3802-123-27 | | SERIAL NO. 10/824,796 | |
| LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary) | | | | APPLICANT Michael KADAN, et al. | | | |
| | | | | FILING DATE April 14, 2004 | | GROUP ART UNIT 1646 | |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|---------------------|--------------------|--------------|-------------------|-------|--------------|-------------------------------|
| BLi | AA | 2001/0053352 | YU et al. | — | — | |
| ↓ | AB | 5,689,433 | KISTNER et al. | — | — | |
| ↓ | AC | 5,871,726 | HENDERSON et al. | — | — | |
| ↓ | AD | 5,998,205 | HALLENBECK et al. | — | — | |
| ↓ | AE | 6,432,700 | HENDERSON et al. | — | — | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES NO | |
|--------------------|------|---------|-----------------------|--|
| AF | | | | |
| AG | | | | |
| AH | | | | |
| AI | | | | |
| AJ | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|----|--|
| BLi | AP | Wu, et al., "Incorporation of Adenovirus into a Ligand-based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression", Journal of Biological Chemistry, Vol. 269, No. 15, pp. 11542-1546, 1994. |
| ↓ | AQ | Sato, et al., "Enhanced and Specific Gene Expression via Tissue-Specific Production of Cre Recombinase Using Adenovirus Vector", Biochemical and Biophysical Research Communications, Vol. 244, pp. 455-462, 1998. |
| ↓ | AR | American Type Culture Collection (ATTC) Website, ATTC Number CCE - 2.2, Designation HeLa S3, 2004. |
| ↓ | AS | Gorziglia, et al., "Generation of an Adenovirus Vector Lacking E1, E2a, E3, and All of E4 except Open Reading Frame 3", Vol. 73, No. 7, Journal of Virology, pp. 6048-6055, 1999. |
| ↓ | AT | Burger, et al., "Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice", British Journal of Haematology, Vol. 108, pp. 641-652, 2000. |

| | |
|---|---|
| EXAMINER BLi | DATE CONSIDERED 02/15/2006 |
|---|---|

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PTO/SB/08a (05-01)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

class
subclasses

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------------------|--------------------------|--|-----------------|--------------------------------|--|---|
| Examiner Initials ¹ | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ¹ (if known) | | | | |
| BCL | | US- 5677178 | | 10-14-1997 | McCormick, F. | |
| | | US- 5698443 | | 12-16-1997 | Henderson | |
| | | US- 5770442 | | 06-23-1998 | Wickham | |
| | | US- 5801029 | | 09-01-1998 | McCormick, F. | |
| | | US- 5830686 | | 11-03-1998 | Henderson | |
| | | US- 5891690 | | 11-30-1999 | Massie | |
| | | US- 5994128 | | 11-30-1999 | Fallaux | |
| | | US- 5998205 | | 12-07-1999 | Hallenbeck | |
| | | US- 6033908 | | 03-07-2000 | Bout | |
| | | US- 6365394 | | 04-02-2002 | Gao | |
| | | US- 6432700 | | 08-20-2002 | Henderson | |
| | | US- 6436394 | | 08-20-2002 | Henderson | |
| | | US- 6495130 | | 12-17-2002 | Henderson | |
| | | US- 6551587 | | 04-22-2003 | Hallenbeck | |
| | | US- 6585968 | | 07-01-2003 | Little | |
| | | US- 6638762 | | 10-28-2003 | Chang | |
| | | US- 6676935 | | 01-13-2004 | Henderson | |
| | | US- 6692736 | | 02-17-2004 | Yu | |
| | | US- 20010053352 | | 12-20-2001 | Yu | |
| | ✓ | | US- 20020120117 | | 08-29-2002 | Zhang |
| | | US- 20020136707 | | 09-26-2002 | Yu | |
| | | US- 20020192187 | | 12-19-2002 | McClelland | |
| | | US- 20030026792 | | 02-06-2003 | Lamparsky | |
| | | US- 20030068307 | | 04-10-2003 | Yu | |
| | | US- 20030152553 | | 08-14-2003 | Henderson | |
| | | US- 20030039633 | | 02-27-2003 | Yu | |
| | | US- 20030104625 | | 06-05-2003 | Cheng/Ennist | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials' | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ^o |
| | | Country Code ² -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | | | | | |

| | | | |
|-----------------------|-----|--------------------|------------|
| Examiner Signature | BZi | Date Considered | 02/15/2006 |
|-----------------------|-----|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP §01.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|--|---|----|--------------------------|----------------|
| Substitute for form 1449B/PTO | | | Complete if Known | |
| | | | Application Number | 10/824,796 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Filing Date | April 14, 2004 |
| | | | First Named Inventor | KADAN, MICHAEL |
| | | | Group Art Unit | 1646 |
| | | | Examiner Name | |
| (use as many sheets as necessary) | | | Attorney Docket Number | GTIN-007 |
| Sheet | 2 | of | 5 | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
| | | Country Code ² -Number ³ -Kind Code ⁴ <small>(if known)</small> | | | | |
| BLi | | WO 00/15820 | 03-23-2000 | YU | | |
| | | WO 02/067861 | 09-08-2000 | CHENG | | |
| | | WO 02/068627 | 09-06-2002 | GORZIGLIA | | |
| | | WO 03/07859 | 01-30-2003 | YU | | |
| | | WO 03/104476 | 12-18-2003 | BOWE | | |
| | | WO 04/042025 | 05-21-2004 | YU | | |
| | | WO 92/03563 | 03-05-1992 | GLAZENBUR | | |
| | | WO 95/19434 | 07-20-1995 | HENDERSON | | |
| | | WO 95/34671 | 12-21-1995 | KOVESDI | | |
| | | WO 96/17053 | 06-06-1996 | HALL ENBEC | | |
| | | WO 96/18418 | 06-20-1996 | KADAN | | |
| | | WO 98/13499 | 04-02-1998 | NEMEROW | | |
| | | WO 98/39464 | 09-11-1998 | HENDERSON | | |
| | | WO 98/39465 | 09-11-1998 | LITTLE | | |
| | | WO 98/39466 | 09-11-1998 | YU | | |
| | | WO 98/39467 | 09-11-1998 | LAMPARSKY | | |
| | WO 99/06576 | 02-11-1999 | YU | | | |
| | WO 99/25860 | 05-27-1999 | CHANG | | | |

| OTHER ART—NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>publisher, city, and/or country, where published</small> | T ² |
| BLi | | BLACKWOOD et al., GOING THE DISTANCE: A CURRENT VIEW OF ENHANCER ACTION, Science, 1998, 281:60-63 | |
| BLi | | DORONIN et al., TUMOR-SPECIFIC, REPLICATION-COMPETENT ADENOVIRUS VECTORS OVEREXPRESSING THE ADENOVIRUS DEATH PROTEIN, Journal of Virology, 2000, 74(13):6147-6155 | |
| BLi | | DORONIN et al., TISSUE-SPECIFIC, TUMOR-SELECTIVE, REPLICATION-COMPETENT ADENOVIRUS VECTOR FOR CANCER GENE THERAPY, Journal of Virology, 2001, 75(7):3314-3324 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BLi 02/15/2006

class
subclass

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|----------|
| Substitute for form 1449B/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/824,796 | |
| | | | Filing Date | April 14, 2004 | |
| | | | First Named Inventor | KADAN, MICHAEL | |
| | | | Group Art Unit | 1646 | |
| | | | Examiner Name | | |
| Sheet | 3 | of | 5 | Attorney Docket Number | GTIN-007 |

| OTHER ART—NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>publisher, city and/or country where published</small> | 2 |
| BLI | | DORONIN et al., OVEREXPRESSION OF THE ADP (E3-11.6K) PROTEIN INCREASES CELL LYSIS AND SPREAD OF ADENOVIRUS, Virology, 2003, Jan 20;305(2):378-87. | |
| | | FALLAUX et al., NEW HELPER CELLS AND MATCHED EARLY REGION 1-DELETED ADENOVIRUS VECTORS PREVENT GENERATION OF REPLICATION-COMPETENT ADENOVIRUSES, Human Gene Therapy, 1998, 9:1909-1917 | |
| | | GRAHAM et al., CHARACTERISTICS OF A HUMAN CELL LINE TRANSFORMED BY DNA FROM HUMAN ADENOVIRUS TYPE 5, J. Gen. Virol., 1977, 36:59-72 | |
| | | HABIB et al., E1B-DELETED ADENOVIRUS (d1520) GENE THERAPY FOR PATIENTS WITH PRIMARY AND SECONDARY LIVER TUMORS, Human Gene Therapy, 2001, 12:219-226 | |
| | | HeLa-S3 -ATCC number CCL-2.2 | |
| | | JAKUBCZAK et al., CONSTRUCTION AND CHARACTERIZATION OF ONCOLYTIC ADENOVIRUSES, Molecular Therapy, 2001, 3(5):Abstract 442 | |
| ✓ | | KIM et al., DEVELOPMENT OF A PACKAGING CELL LINE FOR PROPAGATION OF REPLICATION-DEFICIENT ADENOVIRUS VECTOR, Exp. Mol. Med., 2001, 33(3)145-9 | |

| | | | |
|-----------------------|-----|--------------------|------------|
| Examiner Signature | BLI | Date Considered | 02/15/2005 |
|-----------------------|-----|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|----------|
| Substitute for form 1449B/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/824,796 | |
| | | | Filing Date | April 14, 2004 | |
| | | | First Named Inventor | KADAN, MICHAEL | |
| | | | Group Art Unit | 1646 | |
| | | | Examiner Name | | |
| Sheet | 4 | of | 5 | Attorney Docket Number | GTIN-007 |

| OTHER ART—NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| BLI | | KRUYT et al., TOWARD A NEW GENERATION OF CONDITIONALLY REPLICATING ADENOVIRUSES: PAIRING TUMOR SELECTIVITY WITH MAXIMAL ONCOLYSIS, Human Gene Therapy, 2002, 13(4):485-495 | |
| | | KWONG et al., COMBINATION THERAPY WITH SUICIDE AND CYTOKINE GENES FOR HEPATIC METASTASES OF LUNG CANCER, Chest, 1997, 112(5):1332-1337 | |
| | | NEMUNAITIS et al., SELECTIVE REPLICATION AND ONCOLYSIS IN p53 MUTANT TUMORS WITH ONYX-015, AN E1B-55Kd GENE-DELETED ADENOVIRUS, IN PATIENTS WITH ADVANCED HEAD AND NECK CANCER: A PHASE II TRIAL, Cancer Research, 2000, 60:6359-6366 | |
| | | RUSSELL, UPDATE ON ADENOVIRUS AND ITS VECTORS, Journal of General Virology, 2000, 81:2573-2604 | |
| | | SAUTHOFF et al., DELETION OF THE ADENOVIRAL E1b-19Kd GENE ENHANCES TUMOR CELL KILLING OF A REPLICATING ADENOVIRAL VECTOR, Human Gene Therapy, 2000, 11:379-388 | |
| | | SCHIEDNER et al., EFFICIENT TRANSFORMATION OF PRIMARY HUMAN AMNIOCYTES BY E1 FUNCTIONS OF Ad5: GENERATION OF NEW CELL LINES FOR ADENOVIRAL VECTOR PRODUCTION, 2002, Human Gene Therapy, 11:2105-2116 | |

| | | | |
|-----------------------|-----|--------------------|------------|
| Examiner Signature | BLI | Date Considered | 02/15/2005 |
|-----------------------|-----|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|----------------|------------------------|----------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/824,796 | | |
| | | Filing Date | April 14, 2004 | | |
| | | First Named Inventor | KADAN, MICHAEL | | |
| | | Group Art Unit | 1646 | | |
| | | Examiner Name | | | |
| Sheet | 5 | of | 5 | Attorney Docket Number | GTIN-007 |

| OTHER ART—NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |

| | | | |
|-----|--|--|--|
| BCi | | SMITH et al., TRANSCRIPTIONAL REGULATION OF MAMMALIAN GENES IN VIVO, 1997, J. Biol. Chem. 272:27493-27496 | |
| | | STEINWAERDER et al., INSULATION FROM VIRAL TRANSCRIPTIONAL REGULATORY ELEMENTS IMPROVES INDUCIBLE TRANSGENE EXPRESSION FROM ADENOVIRUS VECTORS IN VITRO AND IN VUVVO, Gene Therapy, 2000, 7(7):556-567 | |
| | | YU et al., SELECTIVELY REPLICATING ONCOLYTIC ADENOVIRUSES AS CANCER THERAPEUTICS, Current Opinion in Molecular Therapeutics, 2002, 4(5), pp: 435-443 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BCi 02/15/2006